Business Context and Reporting Period
Company: NewAmsterdam Pharma Company N.V.
Filing Type: Form 8-K (Current Report)
Date of Report: March 2, 2026
Reporting Period: Single event date (March 2, 2026)
Business Context: The filing serves as a Regulation FD disclosure to announce the posting of an updated corporate investor presentation on the company's website.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice regarding the release of a presentation rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed within the text of this filing. The only reported event is the publication of the corporate investor presentation (Exhibit 99.1).
Guidance, Outlook, and Risks
Management Commentary: The company directed investors to its website for the updated corporate presentation.
Legal Disclaimer: The information in Item 7.01 and Exhibit 99.1 is "furnished" and not "filed" under the Securities Exchange Act of 1934. Consequently, it is not subject to the liabilities of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act of 1933, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the content of the "Corporate Presentation" dated March 2, 2026, available as Exhibit 99.1 on the company website.
- Confirm that the presentation contains the latest financial guidance and operational updates, as the 8-K text itself contains no such data.
- Note that the presentation is not legally "filed" with the SEC and carries different liability standards than the 8-K form itself.